The Endocrine Society guidelines on hormonal replacement in postmenopausal women advise that the underlying individual risk for breast cancer must be considered. Nonhormonal therapies are recommended for women at high or intermediate risk for breast cancer who are considering hormone therapy to alleviate severe vasomotor symptoms associated with menopause. The same guidelines recommend against the use of tibolone in women with a history of breast cancer.
HRT containing both estrogen and progestin is associated with the highest risk for heart disease and breast cancer, whereas the degree of risk appears to be lower for women who take estrogen alone. The effect of HRT on breast cancer risk also depends on the individual risk of developing breast cancer.
Learn more about menopausal HRT.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Pavani Chalasani, Stefania Morganti. Fast Five Quiz: Advanced and Metastatic Breast Cancer Myths - Medscape - Apr 20, 2023.